Eyepoint Pharmaceuticals Inc. (NASDAQ:EYPT) – Corporate Update
Trading Snapshot
- Closing Price (23 Feb 2026): USD 0.41
- Price Change: 0 % over the last 24 hours
- Volume Traded: USD 5.4 million (≈ 13 million shares)
- Market Capitalisation: USD 37.1 million
- Total Shares Outstanding: 86.2 million
- Simple Moving Average (200 days): USD 11.46
- 52‑Week High: USD 19.11 (08 Dec 2025)
- 52‑Week Low: USD 0.39 (21 Oct 2026)
- Year‑to‑Date Performance (since 31 Jan 2026): –88.44 %
Analyst Outlook
| Rating Firm | Rating | Price Target (USD) | Notes |
|---|---|---|---|
| Laidlaw | Hold | 0.50 | Reaffirmed hold stance |
| Mizuho | Neutral | 0.55 | Modest target, neutral view |
| Jefferies | Hold | 0.60 | Downgraded due to trial concerns |
| Cantor Fitzgerald | Neutral | 0.75 | Neutral rating, trial outcomes cited |
- Overall sentiment remains uncertain, with price targets ranging from USD 0.50 to USD 1.00.
- The company’s most recent quarterly results indicated a modest revenue increase but sustained net losses, prompting analysts to forecast negative earnings for the fiscal year.
Institutional Activity
- Several institutional funds have adjusted positions in Eyepoint, reflecting ongoing interest despite the cautious outlook.
- No large buy or sell blocks were reported in the last 24 hours.
Comparative Performance of Related Stocks (Last 24 Hours)
- Grove Collaborative (GROV): +2.51 % → USD 1.06; Market Cap: USD 43.6 million
- Actinium (ATNM): +15.94 % → USD 1.50; Market Cap: USD 43.4 million; P/E: 3.87
- Marathon (MBBC): –2.42 % → USD 14.50; Market Cap: USD 43.5 million; P/E: 21.91
- Heritage Global (HGBL): –2.34 % → USD 1.26; Market Cap: USD 44.3 million
- Elicio Therapeutics (9HA.F): –12.36 % → USD 1.95; Market Cap: USD 43.9 million
Company Overview
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical enterprise focused on developing drug delivery devices for ocular and chronic conditions. The company operates globally and maintains an online presence at www.eyepointpharma.com . It commenced public trading on the Nasdaq exchange on 27 January 2005.
